Nanoparticle-mediated Targeting of the Fusion Gene RUNX1/ETO in t(8;21)-positive Acute Myeloid Leukemia [RNA-seq]

To investigate the therapeutic potential of targeting RUNX1/ETO with lipid nanoparticles encapsulating chemically modefied siRNA. Gene expression profiling was performing on cells lines after lipid nanoparticles in vitro and on harvested cells from treated mice in vivo. Comparative gene expression profiling analysis of RNA-seq data for Kasumi-1 and KSNO-1 cells from in vitro treatment with active siRNA against RUNX1/ETO (LNP/siRE-mod) and control siRNA (LNP/siMM-mod). In vivo treatment of RG mice engrafted with Kasumi-1 cells and treated with active siRNA against RUNX1/ETO (LNP/siRE-mod) and control siRNA (LNP/siMM-mod)